Biotech | August 08, 2021
Strides Pharma reports Q1FY22 consolidated loss at Rs 205.2 Cr
The company expects revenue growth of 10-15 per cent in the US
The company expects revenue growth of 10-15 per cent in the US
The transaction is expected to close in the Q4FY22
India business contributes to a stellar performance
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
Advances deployment of mRNA technology across vaccines and therapeutics development
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
CDSCO to fast-track trials and approval for COVID19 vaccine
Releasing it, Union Minister Jitendra Singh said India needs its database for Indian research and solutions.
Deal for 100 million doses with additional 100 million through 2023
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
Subscribe To Our Newsletter & Stay Updated
